These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27317851)

  • 1. Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites.
    Zhou Y; Orešič M; Leivonen M; Gopalacharyulu P; Hyysalo J; Arola J; Verrijken A; Francque S; Van Gaal L; Hyötyläinen T; Yki-Järvinen H
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1463-1472.e6. PubMed ID: 27317851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a Scoring System, Based on Genetic and Clinical Factors, to Determine Risk of Steatohepatitis in Asian Patients with Nonalcoholic Fatty Liver Disease.
    Koo BK; Joo SK; Kim D; Lee S; Bae JM; Park JH; Kim JH; Chang MS; Kim W
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2592-2599.e10. PubMed ID: 32062042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters.
    Chunming L; Jianhui S; Hongguang Z; Chunwu Q; Xiaoyun H; Lijun Y; Xuejun Y
    Turk J Gastroenterol; 2015 Sep; 26(5):408-16. PubMed ID: 26215061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-based study on the prevalence of NASH using scores validated against liver histology.
    Hyysalo J; Männistö VT; Zhou Y; Arola J; Kärjä V; Leivonen M; Juuti A; Jaser N; Lallukka S; Käkelä P; Venesmaa S; Simonen M; Saltevo J; Moilanen L; Korpi-Hyövalti E; Keinänen-Kiukaanniemi S; Oksa H; Orho-Melander M; Valenti L; Fargion S; Pihlajamäki J; Peltonen M; Yki-Järvinen H
    J Hepatol; 2014 Apr; 60(4):839-46. PubMed ID: 24333862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
    Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease.
    Nobili V; Donati B; Panera N; Vongsakulyanon A; Alisi A; Dallapiccola B; Valenti L
    J Pediatr Gastroenterol Nutr; 2014 May; 58(5):632-6. PubMed ID: 24345846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
    Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H
    Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.
    Kamada Y; Ono M; Hyogo H; Fujii H; Sumida Y; Mori K; Tanaka S; Yamada M; Akita M; Mizutani K; Fujii H; Yamamoto A; Takamatsu S; Yoshida Y; Itoh Y; Kawada N; Chayama K; Saibara T; Takehara T; Miyoshi E
    Hepatology; 2015 Nov; 62(5):1433-43. PubMed ID: 26199205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.
    Kotronen A; Peltonen M; Hakkarainen A; Sevastianova K; Bergholm R; Johansson LM; Lundbom N; Rissanen A; Ridderstråle M; Groop L; Orho-Melander M; Yki-Järvinen H
    Gastroenterology; 2009 Sep; 137(3):865-72. PubMed ID: 19524579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study.
    Gao F; Zheng KI; Chen SD; Lee DH; Wu XX; Wang XD; Targher G; Byrne CD; Chen YP; Kim W; Zheng MH
    Clin Transl Gastroenterol; 2021 Mar; 12(3):e00321. PubMed ID: 33704100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease.
    Hendy OM; Elsabaawy MM; Aref MM; Khalaf FM; Oda AMA; El Shazly HM
    APMIS; 2017 Jul; 125(7):607-613. PubMed ID: 28430371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of a Novel Scoring System for Noninvasive Nonalcoholic Steatohepatitis Detection in Bariatric Patients.
    Billeter AT; Wloka S; Behnisch R; Albrecht T; Roessler S; Goeppert B; Mueller S; Nickel F; Müller B
    Obes Facts; 2021; 14(5):490-500. PubMed ID: 34419953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
    Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
    Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis.
    Qi S; Xu D; Li Q; Xie N; Xia J; Huo Q; Li P; Chen Q; Huang S
    Clin Chim Acta; 2017 Oct; 473():89-95. PubMed ID: 28842175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.
    Valenti L; Alisi A; Galmozzi E; Bartuli A; Del Menico B; Alterio A; Dongiovanni P; Fargion S; Nobili V
    Hepatology; 2010 Oct; 52(4):1274-80. PubMed ID: 20648474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivation and validation of a scoring system for predicting nonalcoholic steatohepatitis in Taiwanese patients with severe obesity.
    Tai CM; Yu ML; Tu HP; Huang CK; Hwang JC; Chuang WL
    Surg Obes Relat Dis; 2017 Apr; 13(4):686-692. PubMed ID: 28089433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients.
    Francque SM; Verrijken A; Mertens I; Hubens G; Van Marck E; Pelckmans P; Michielsen P; Van Gaal L
    Clin Gastroenterol Hepatol; 2012 Oct; 10(10):1162-8; quiz e87. PubMed ID: 22796457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.